🍽️ enoxacin (antibiotic)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Treatment of Bacterial Infections: Enoxacin is used to treat various bacterial infections, including urinary tract infections (UTIs), respiratory tract infections, skin and soft tissue infections, bone and joint infections, and sexually transmitted infections (STIs) such as gonorrhea.

  2. Gram-Negative and Gram-Positive Coverage: Enoxacin exhibits activity against both Gram-negative and Gram-positive bacteria. It can target pathogens such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Staphylococcus aureus, Streptococcus pneumoniae, and others.

  3. UTIs and Prostatitis: Enoxacin is particularly effective in treating urinary tract infections, including complicated and uncomplicated UTIs, as well as prostatitis (inflammation of the prostate gland) caused by susceptible bacteria.

  4. Respiratory Infections: It can be used to treat respiratory tract infections, including bronchitis and pneumonia caused by susceptible bacteria.

  5. Skin and Soft Tissue Infections: Enoxacin may be prescribed for skin and soft tissue infections, such as cellulitis and wound infections, when caused by susceptible organisms.

  6. Bone and Joint Infections: In some cases, enoxacin can be used to treat bone and joint infections caused by susceptible bacteria, although it may not be the first-line choice for these infections.

  7. Gonorrhea: Enoxacin was previously used to treat gonorrhea, but its use has decreased due to the emergence of resistant strains. It may still be effective against some gonorrhea strains in regions where resistance rates are low.

  8. Side Effects: Like other fluoroquinolone antibiotics, enoxacin can cause various side effects, including gastrointestinal symptoms (nausea, vomiting, diarrhea), central nervous system effects (headache, dizziness, insomnia), and musculoskeletal effects (tendonitis, tendon rupture). Rare but serious adverse effects include peripheral neuropathy, hypersensitivity reactions, and potentially irreversible damage to tendons, muscles, joints, nerves, and the central nervous system.

  9. Drug Interactions: Enoxacin may interact with other medications, including antacids, sucralfate, iron supplements, and certain anticoagulants, potentially reducing its absorption or efficacy.

  10. Precautions: Enoxacin should be used with caution in patients with a history of seizures, renal impairment, myasthenia gravis, or other neurological disorders. It is generally not recommended for use in children, pregnant women, or breastfeeding mothers unless the benefits outweigh the risks.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of enoxacin (antibiotic) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by enoxacin (antibiotic)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Clostridium genus Decreases 👪 Source Study Pathogen
Escherichia genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Segatella genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Bacteroides genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Blautia genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Akkermansia genus Decreases 📓 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Eubacterium (in: firmicutes) no rank Decreases ⚗️ Source Study
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Odoribacter splanchnicus species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Collinsella aerofaciens species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
[Ruminococcus] torques species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Parabacteroides distasonis species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Roseburia intestinalis species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Ruminococcus bromii species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
Akkermansia glycaniphila species Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of enoxacin (antibiotic) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.5 0.5
Acne 0.2 -0.2
ADHD 5.9 1 4.9
Age-Related Macular Degeneration and Glaucoma 1 0.5 1
Allergic Rhinitis (Hay Fever) 3 1 2
Allergies 6.9 3.1 1.23
Allergy to milk products 2.5 1.2 1.08
Alopecia (Hair Loss) 2.5 2.5
Alzheimer's disease 6.3 9.2 -0.46
Amyotrophic lateral sclerosis (ALS) Motor Neuron 3.8 1.7 1.24
Ankylosing spondylitis 6.1 2.6 1.35
Anorexia Nervosa 0.5 3.1 -5.2
Antiphospholipid syndrome (APS) 3.4 0.5 5.8
Asthma 1.7 1.3 0.31
Atherosclerosis 1.7 3.1 -0.82
Atrial fibrillation 4.7 3.2 0.47
Autism 14.9 11.6 0.28
Barrett esophagus cancer 1 0.4 1.5
benign prostatic hyperplasia 0.5 0.5
Biofilm 3.8 3.8
Bipolar Disorder 2.5 2.5 0
Brain Trauma 0.7 1 -0.43
Cancer (General) 0.5 3.5 -6
Carcinoma 5.6 3.7 0.51
Celiac Disease 3.9 4.8 -0.23
Cerebral Palsy 1.7 2 -0.18
Chronic Fatigue Syndrome 11.5 11.6 -0.01
Chronic Kidney Disease 4 2.6 0.54
Chronic Lyme 1 -1
Chronic Obstructive Pulmonary Disease (COPD) 3.2 1.1 1.91
Chronic Urticaria (Hives) 2.9 2.2 0.32
Coagulation / Micro clot triggering bacteria 2.4 1.9 0.26
Colorectal Cancer 7.6 1.2 5.33
Constipation 2.1 1 1.1
Coronary artery disease 2.5 1.5 0.67
COVID-19 15.6 19 -0.22
Crohn's Disease 12.7 7.7 0.65
cystic fibrosis 1.5 1.2 0.25
deep vein thrombosis 1.5 1.4 0.07
Depression 13.5 11.4 0.18
Dermatomyositis 0.4 0.2 1
Eczema 2 3.1 -0.55
Endometriosis 4.6 1.6 1.87
Eosinophilic Esophagitis 0.5 0.5 0
Epilepsy 4.2 3 0.4
Fibromyalgia 3.4 4.2 -0.24
Functional constipation / chronic idiopathic constipation 8.2 6.2 0.32
gallstone disease (gsd) 3.5 1.2 1.92
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 3 1.4 1.14
Generalized anxiety disorder 3.5 2.1 0.67
giant cell arteritis 0.5 -0.5
Glioblastoma 0.4 -0.4
Gout 0.5 -0.5
Graves' disease 1.7 2 -0.18
Halitosis 1.5 0.4 2.75
Hashimoto's thyroiditis 3.3 1.2 1.75
Hidradenitis Suppurativa 1.4 0.5 1.8
High Histamine/low DAO 3 0.7 3.29
hypercholesterolemia (High Cholesterol) 1 0.2 4
hyperglycemia 0.6 2 -2.33
Hyperlipidemia (High Blood Fats) 0.8 0.5 0.6
hypersomnia 1 -1
hypertension (High Blood Pressure 3.2 7.4 -1.31
Hypothyroidism 1.7 -1.7
Hypoxia 1.1 1.1
IgA nephropathy (IgAN) 6 -6
Inflammatory Bowel Disease 6.6 11.5 -0.74
Insomnia 1.4 1.1 0.27
Intelligence 2 1 1
Intracranial aneurysms 2 0.5 3
Irritable Bowel Syndrome 6.4 5.5 0.16
Liver Cirrhosis 7.2 4.7 0.53
Long COVID 11.9 11.3 0.05
Low bone mineral density 1.1 -1.1
Lung Cancer 1.5 1.7 -0.13
Mast Cell Issues / mastitis 0.9 1.2 -0.33
ME/CFS with IBS 1.9 3.7 -0.95
ME/CFS without IBS 3.6 3.2 0.13
Menopause 1.8 1.8
Metabolic Syndrome 12.7 11.2 0.13
Mood Disorders 17.7 11.9 0.49
multiple chemical sensitivity [MCS] 2.1 0.5 3.2
Multiple Sclerosis 7.6 8.2 -0.08
Multiple system atrophy (MSA) 2 1.2 0.67
neuropathic pain 1.8 -1.8
Neuropathy (all types) 1 0.5 1
neuropsychiatric disorders (PANDAS, PANS) 1.5 1.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 3.9 5.8 -0.49
NonCeliac Gluten Sensitivity 0.2 -0.2
Obesity 13.2 6.6 1
obsessive-compulsive disorder 10.5 6.4 0.64
Osteoarthritis 2.9 0.5 4.8
Osteoporosis 3 1.2 1.5
pancreatic cancer 0.9 0.9
Parkinson's Disease 4.5 6.5 -0.44
Polycystic ovary syndrome 4 2.7 0.48
Postural orthostatic tachycardia syndrome 0.5 0.7 -0.4
Premenstrual dysphoric disorder 1.2 0.5 1.4
primary biliary cholangitis 0.5 1.5 -2
Psoriasis 6.7 4.2 0.6
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 10.3 5.7 0.81
Rosacea 1.7 1 0.7
Schizophrenia 8.8 2.6 2.38
scoliosis 0.5 1.3 -1.6
Sjögren syndrome 4.9 4 0.23
Sleep Apnea 2.2 2.5 -0.14
Slow gastric motility / Gastroparesis 2.5 0.2 11.5
Small Intestinal Bacterial Overgrowth (SIBO) 1.9 0.4 3.75
Stress / posttraumatic stress disorder 4.3 3.4 0.26
Systemic Lupus Erythematosus 7.4 2.3 2.22
Tic Disorder 2 2.2 -0.1
Tourette syndrome 0.1 0.5 -4
Type 1 Diabetes 6.5 2.9 1.24
Type 2 Diabetes 13.2 10.6 0.25
Ulcerative colitis 4.4 8 -0.82
Unhealthy Ageing 10.4 2.8 2.71

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]